Patents by Inventor William Roush

William Roush has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
    Publication number: 20200087270
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
    Type: Application
    Filed: September 16, 2019
    Publication date: March 19, 2020
    Inventors: Luigi FRANCHI, Shomir GHOSH, Gary GLICK, Jason KATZ, Anthony William OPIPARI, Jr., William ROUSH, Hans Martin SEIDEL, Dong-Ming SHEN, Shankar VENKATRAMAN, David Guenther WINKLER
  • DUAL VARIABLE DOMAIN IMMUNOCONJUGATES AND USES THEREOF
    Publication number: 20180250415
    Abstract: Dual variable domain (DVD) immunoconjugates and uses thereof are provided. Aspects of the subject immunoconjugates include a DVD immunoglobulin molecule having a first and a second variable domain, and a cargo moiety (e.g., a drug moiety) that is covalently conjugated to the second variable domain via a linker. Methods of making and using the subject immunoconjugates in the prevention and/or treatment of cancer and other diseases are also provided.
    Type: Application
    Filed: September 16, 2016
    Publication date: September 6, 2018
    Inventors: Christoph Rader, Alex Nanna, William Roush
  • Conversion of glycerol to 1,3-propanediol under haloalkaline conditions
    Patent number: 9328360
    Abstract: A method of producing 1,3-propanediol. The method comprises fermenting a haloalkaliphilic species of Halanaerobium with a source of glycerol into 1,3-propanediol, at a pH of greater than about 10 and at a salt concentration of greater than about 5% w/v. Furthermore, with supplementation of vitamin B12, the yield of 1,3-propanediol to glycerol can be increased.
    Type: Grant
    Filed: September 6, 2014
    Date of Patent: May 3, 2016
    Assignee: The Curators of the University of Missouri
    Inventors: Melanie Rose Mormile, Daniel William Roush, Dwayne Alexander Elias, Oliver Clifford Sitton
  • CONVERSION OF GLYCEROL TO 1,3-PROPANEDIOL UNDER HALOALKALINE CONDITIONS
    Publication number: 20150072388
    Abstract: A method of producing 1,3-propanediol. The method comprises fermenting a haloalkaliphilic species of Halanaerobium with a source of glycerol into 1,3-propanediol, at a pH of greater than about 10 and at a salt concentration of greater than about 5% w/v. Furthermore, with supplementation of vitamin B12, the yield of 1,3-propanediol to glycerol can be increased.
    Type: Application
    Filed: September 6, 2014
    Publication date: March 12, 2015
    Inventors: Melanie Rose Mormile, Daniel William Roush, Dwayne Alexander Elias, Oliver Clifford Sitton
  • Method of treating viral diseases
    Publication number: 20050026910
    Abstract: The present invention relates to novel chemical compounds, methods for their discovery, and therapeutic use. In particular, the present invention provides benzimidazole derivatives and methods of using benzimidazole derivatives as therapeutic agents to treat a number of conditions associated with retroviral infection.
    Type: Application
    Filed: June 28, 2004
    Publication date: February 3, 2005
    Applicant: The Regents of the University of Michigan
    Inventors: William Roush, Nan Zheng, Vassil St. Georgiev
  • Synthesis of clasto-lactacystin ?-lactone and analogs thereof
    Patent number: 6849743
    Abstract: The present invention is directed to an improved synthesis of clasto-lactacystin-?-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-?-lactones, and analogs thereof and their use as proteasome inhibitors.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: February 1, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: François Soucy, Louis Flamondon, Mark Behnke, William Roush
  • Synthesis of clasto-lactacystin &bgr;-lactone and analogs thereof
    Patent number: 6794516
    Abstract: The present invention is directed to an improved synthesis of clasto-lactacystin-&bgr;-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-&bgr;-lactones, and analogs thereof and their use as proteosome inhibitors.
    Type: Grant
    Filed: February 7, 2003
    Date of Patent: September 21, 2004
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: François Soucy, Louis Plamondon, Mark Behnke, William Roush
  • Synthesis of clasto-lactacystin beta-lactone and analogs thereof
    Publication number: 20040171608
    Abstract: The present invention is directed to an improved synthesis of clasto-lactacystin-&bgr;-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-&bgr;-lactones, and analogs thereof and their use as proteasome inhibitors.
    Type: Application
    Filed: December 18, 2003
    Publication date: September 2, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Francois Soucy, Louis Flamondon, Mark Behnke, William Roush
  • Synthesis of clasto-lactacystin beta-lactone and analogs thereof
    Publication number: 20030191322
    Abstract: The present invention is directed to an improved synthesis of clasto-lactacystin-&bgr;-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-&bgr;-lactones, and analogs thereof and their use as proteosome inhibitors.
    Type: Application
    Filed: February 7, 2003
    Publication date: October 9, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Francois Soucy, Louis Plamondon, Mark Behnke, William Roush
  • Synthesis of clasto-lactacystin &bgr;-lactone and analogs thereof
    Patent number: 6566553
    Abstract: The present invention is directed to an improved synthesis of clasto-lactacystin-&bgr;-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-&bgr;-lactones, and analogs thereof and their use as proteosome inhibitors.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: May 20, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: François Soucy, Louis Plamondon, Mark Behnke, William Roush
  • Synthesis of clasto-lactacystin beta-lactone and analogs thereof
    Publication number: 20020016355
    Abstract: The present invention is directed to an improved synthesis of clasto-lactacystin-&bgr;-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-&bgr;-lactones, and analogs thereof and their use as proteosome inhibitors.
    Type: Application
    Filed: August 10, 2001
    Publication date: February 7, 2002
    Inventors: Francois Soucy, Louis Plamondon, Mark Behnke, William Roush
  • Synthesis of clasto-lactacystin &bgr;-lactone and analogs thereof
    Patent number: 6294560
    Abstract: The present invention is directed to an improved synthesis of clasto-lactacystin-&bgr;-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-&bgr;-lactones, and analogs thereof and their use as proteosome inhibitors.
    Type: Grant
    Filed: June 20, 2000
    Date of Patent: September 25, 2001
    Assignee: Millennium Pharmaceuticals, Inc..
    Inventors: François Soucy, Louis Plamondon, Mark Behnke, William Roush
  • Synthesis of clasto-lactacystin beta-lactone and analogs thereof
    Patent number: 6133308
    Abstract: The present invention is directed to an improved synthesis of clasto-lactacystin-.beta.-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-.beta.-lactones, and analogs thereof and their use as proteosome inhibitors.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: October 17, 2000
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Fran.cedilla.ois Soucy, Louis Plamondon, Mark Behnke, William Roush